文献速递外周动脉疾病

当代股腘动脉支架随机试验的报告缺口

Contemporary Femoropopliteal Stents: Reporting Gaps of Randomized Trials.
PubMed 文献 · Ann Vasc Surg · 2025-04-18

该系统综述与Meta分析依据PRISMA指南,检索Medline、Scopus和Cochrane数据库至2024年2月,纳入17篇文章(11项试验),评估Zilver PTX、Eluvia、Viabahn和Supera支架治疗股腘动脉病变的随机对照试验设计与报告方法。研究发现各研究在结局评估和报告方法上存在相当大的差异,在病变或手术特征及治疗后临床获益方面需建立标准化报告方法。

要点

  • 17篇文章报告11项试验,80%受试者为男性,总体81%为间歇性跛行。
  • 仅3项试验有长期数据(≥36个月)。
  • 术后及随访ABI值、截肢率和支架断裂率分别在6、5和13篇文章中未报告。

核心结论

  • 各研究在结局评估和报告方法上存在相当大的差异,需建立病变或手术特征及治疗后临床获益的标准化报告方法,以促进临床试验结果向实际实践转化。

研究设计与样本

  • 系统综述与Meta分析,遵循PRISMA指南(CRD42024508602),检索Medline(PubMed)、Scopus和Cochrane数据库至2024年2月,纳入报告股腘动脉Zilver PTX、Eluvia、Viabahn和Supera支架安全性和有效性的随机对照试验,共17篇文章(11项试验)。

主要发现

  • 80%的研究个体为男性,患有间歇性跛行(总体81%;Rutherford分级2级:8项试验,29%;3级:8项试验,46%)。
  • 术前平均踝肱指数(ABI)为0.64(0.56-0.72)。
  • 大多数文章缺少流出道血管、流入或流出道疾病治疗及抗血栓方案依从性的详细信息。
  • 仅3项试验有长期数据(≥36个月)。
  • 术后及随访ABI值、截肢率和支架断裂率分别在6、5和13篇文章中未报告。

关键数值与推荐

  • 主要疗效终点的定义在所有研究中相似,但使用的收缩期峰值流速(PSV)比值截断值范围为2.0至2.5(1项研究:2.5;6项研究:2.4;5项研究:2.0)。
  • 治疗后临床获益常定义为Rutherford分级和/或ABI改善,但个体值并不总是提供。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Endovascular literature has been under scrutiny due to perceived poor-quality data. This has been attributed to multiple reasons, including but not limited to smaller sample size, absence of standardization of reporting methodology and investigational treatment protocols, and limited funding resources. The goal of the current study was to review the design of randomized controlled trials investigating contemporary stents for the femoropopliteal segment, with reported >70-80% primary efficacy rate and address issues with their respective reporting methodology. METHODS: This systematic review and meta-analysis was conducted according to the Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA) guidelines (CRD42024508602). The Medline (PubMed), Scopus, and Cochrane databases were reviewed for randomized controlled trials reporting on the safety and efficacy of femoropopliteal Zilver PTX, Eluvia, Viabahn, and Supera stents through February 2024. Data were collected regarding baseline, lesion, and procedural characteristics and postprocedural outcomes. RESULTS: 17 articles were identified, presenting the results of 11 trials. 80% of the studied individuals were males having intermittent claudication (overall 81%; Rutherford class (RC) 2; 8 trials; 29%; RC 3; 8 trials; 46%). The mean preprocedural ankle-brachial index (ABI) was 0.64 (0.56-0.72). Details about run-off vessels, inflow or outflow disease treatment, and antithrombotic regimen compliance were missing in most papers. Only 3 trials had long-term data (≥36 months). Critical information about postprocedural and during follow-up ABI values, amputation rates, and stent fracture rates were not reported in 6, 5, and 13 articles, respectively. The definition of the primary efficacy endpoint was similar in all studies, although the peak systolic velocity (PSV) ratio cutoff that was used ranged from 2.0 to 2.5 (1 study: 2.5; 6 studies: 2.4; 5 studies: 2.0). Post-treatment clinical benefit was often defined as improvement in RC and/or ABI, although individual values were not always provided. CONCLUSION: The studies exhibited considerable variation in assessment of outcomes and reporting methodology. Standardized reporting methods for lesion or procedural characteristics and post-treatment clinical benefit need to be established to facilitate translation of clinical trials results to actual practice.

来源:Ann Vasc Surg,查看原文。版权归原作者所有。

引用

  1. Giannopoulos S, Volteas P, Koudounas G, et al. Contemporary Femoropopliteal Stents: Reporting Gaps of Randomized Trials. Ann Vasc Surg. 2025. PMID: 40254154. doi:10.1016/j.avsg.2025.04.110

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。